RESUMEN
Recent discoveries suggest that the critical events leading to the anti-proliferative activity of the IMiD immunomodulatory agents lenalidomide and pomalidomide in multiple myeloma (MM) cells are initiated by Cereblon-dependent ubiquitination and proteasomal degradation of substrate proteins Ikaros (IKZF1) and Aiolos (IKZF3). By performing kinetic analyses, we found that the downregulation or proteasomal degradation of Ikaros and Aiolos led to specific and sequential downregulation of c-Myc followed by IRF4 and subsequent growth inhibition and apoptosis. Notably, to ensure growth inhibition and cell death, sustained downregulation of Ikaros and Aiolos, c-Myc or IRF4 expression was required. In addition, we found that the half-maximal rate, rather than the final extent of Ikaros and Aiolos degradation, correlated to the relative efficacy of growth inhibition by lenalidomide or pomalidomide. Finally, we observed that all four transcription factors were elevated in primary MM samples compared with normal plasma cells. Taken together, our results suggest a functional link between Ikaros and Aiolos, and the pathological dysregulation of c-Myc and IRF4, and provide a new mechanistic understanding of the relative efficacy of lenalidomide and pomalidomide based on the kinetics of substrate degradation and downregulation of their downstream targets.
Asunto(s)
Antineoplásicos/farmacología , Factor de Transcripción Ikaros/metabolismo , Factores Reguladores del Interferón/metabolismo , Mieloma Múltiple/metabolismo , Proteínas Proto-Oncogénicas c-myc/metabolismo , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Proliferación Celular/fisiología , Regulación hacia Abajo , Citometría de Flujo , Técnicas de Silenciamiento del Gen , Humanos , Immunoblotting , Inmunohistoquímica , Lenalidomida , Mieloma Múltiple/patología , ARN Interferente Pequeño , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Talidomida/análogos & derivados , Talidomida/farmacologíaRESUMEN
AIMS: To test Fountain Flow Cytometry (FFC) for the rapid and sensitive detection of Naegleria lovaniensis amoebae (an analogue for Naegleria fowleri) in natural river waters. METHODS AND RESULTS: Samples were incubated with one of two fluorescent labels to facilitate detection: ChemChrome V6, a viability indicator, and an R-phycoerytherin (RPE) immunolabel to detect N. lovaniensis specifically. The resulting aqueous sample was passed as a stream in front of a light-emitting diode, which excited the fluorescent labels. The fluorescence was detected with a digital camera as the sample flowed toward the imager. Detections of N. lovaniensis were made in inoculated samples of natural water from eight rivers in France and the United States. FFC enumeration yielded results that are consistent with other counting methods: solid-phase cytometry, flow cytometry, and hemocytometry, down to concentrations of 0.06 amoebae ml(-1), using a flow rate of 15 ml min(-1). CONCLUSIONS: This study supports the efficacy of using FFC for the detection of viable protozoa in natural waters and indicates that use of RPE illuminated at 530 nm and detected at 585 nm provides a satisfactory means of attenuating background. SIGNIFICANCE AND IMPACT OF THE STUDY: Because of the severe global public health issues with drinking water and sanitation, there is an urgent need to develop a technique for the real-time detection of viable pathogens in environmental samples at low concentrations. FFC addresses this need.
Asunto(s)
Citometría de Flujo/métodos , Naegleria/aislamiento & purificación , Ríos/parasitología , Animales , Medios de Cultivo , Citometría de Flujo/instrumentación , Técnica del Anticuerpo Fluorescente/métodos , Colorantes Fluorescentes/análisis , Francia , Ficoeritrina/análisis , Reproducibilidad de los Resultados , Estados Unidos , Contaminación del Agua/análisisRESUMEN
To aid our investigation of tubulin as an antileishmanial drug target, the effects of the mammalian antimicrotubule agents ansamitocin P3, taxol, and hemiasterlin on Leishmania donovani promastigotes were described. These drugs affected the assembly of purified leishmanial tubulin and inhibited the growth of L. donovani promastigotes at micromolar concentrations. When promastigotes were treated with these agents, mitotic partitioning of nuclear DNA and cytokinesis were usually inhibited. The spatial orientation of kinetoplasts was often disturbed, suggesting a role for microtubules in the segregation of these organelles during mitosis. Aberrant cell types produced in drug-treated cultures included parasites with one nucleus and two geometrically distinct kinetoplasts, parasites with multiple kinetoplasts, and cytoplasts containing a kinetoplast but no nucleus. A subset of unique cell types, parasites containing two nuclei, a spindle fiber, and two geometrically distinct kinetoplasts, were observed in hemiasterlin-treated cultures. Flow cytometric analysis of L. donovani promastigotes treated with these three drugs indicated a dramatic shift toward the G2 + M phase of the cell cycle, with some cells containing four times the amount of DNA present in G1. These results were used to evaluate the cellular effects of WR85915, an aromatic thiocyanate with in vitro antileishmanial and anti-tubulin activity, on L. donovani. Treatment of parasites with WR85915 did not produce the unusual cell types described above and did not cause the accumulation of parasites in G2 + M, suggesting that WR85915 acts on target(s) in Leishmania in addition to tubulin. These studies validate tubulin as a suitable antileishmanial drug target and provide criteria to assess the cellular mechanism of action of new candidate antileishmanial agents.
Asunto(s)
Leishmania donovani/efectos de los fármacos , Maitansina/análogos & derivados , Maitansina/farmacología , Oligopéptidos/farmacología , Oxadiazoles/farmacología , Paclitaxel/farmacología , Tubulina (Proteína)/metabolismo , Animales , Antiprotozoarios/farmacología , Ciclo Celular/efectos de los fármacos , ADN Protozoario/análisis , Citometría de Flujo , Leishmania donovani/crecimiento & desarrollo , Leishmania donovani/ultraestructura , Microscopía Electrónica , Microscopía FluorescenteRESUMEN
WAY-120,491 [(-)-(3S-trans)-2-[3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromet hox y)- 2H-1-benzopyran-4-yl]-2,3-dihydro-1H-isoindol-1-one] is a novel antihypertensive agent. We have investigated the effects of this compound on contractile force and 86Rb efflux, using the rabbit aorta, in order to assess its K channel activator properties. K channel blockers and ionic conditions thought to modulate specific K channel types have been used to provide insight into the K channel(s) affected by this compound. WAY-120,491 evoked relaxation of precontracted rabbit aortic rings and increased the rate of 86Rb efflux from strips of rabbit aorta; both effects occurring in a concentration-dependent manner. The WAY-120,491 (1 microM)-induced 86Rb efflux was inhibited by tetraethylammonium (IC50 = 0.38 mM), indicating that the increased efflux was mediated by K channels. Glyburide completely blocked the WAY-120,491 (1 microM)-evoked 86Rb efflux with 50% block occurring at a concentration of 0.48 microM. Glyburide also antagonized the WAY-120,491-induced relaxation of aortic rings. Omission of Ca from the solution bathing the aorta did not inhibit the WAY-120,491 induced 86Rb efflux but rather caused an augmentation of the response. It is concluded that WAY-120,491 may be classified as a K channel opener. Furthermore, the K channel upon which WAY-120,491 acts exhibits some characteristics normally associated with the ATP regulated K channel although the involvement of other K channel types has not been ruled out.
Asunto(s)
Antihipertensivos/farmacología , Benzopiranos/farmacología , Indoles/farmacología , Canales de Potasio/efectos de los fármacos , Radioisótopos de Rubidio/metabolismo , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Calcio/fisiología , Relación Dosis-Respuesta a Droga , Gliburida/farmacología , Masculino , Potasio/farmacología , Conejos , Compuestos de Tetraetilamonio/farmacología , Vasoconstricción/efectos de los fármacosRESUMEN
Premenstrual syndrome (PMS) is a very common disorder. It is diagnosed by excluding other disorders, including psychopathology, and with use of a menstrual diary. Although the cause of PMS remains unknown, treatment is usually effective. For the majority of patients, reassurance, dietary changes, and regular exercise are all that is necessary. If this is ineffective, vitamin B6 and, if indicated, vitamin E or zinc sulfate should be added to the regimen. If therapy still is not effective, a diuretic (preferably spironolactone [Aldactone]) or natural progesterone should be added. This may also be done during the three to six months required for dietary therapy to achieve maximum effectiveness. Diuretics are less expensive, easier to use, and easier to obtain than natural progesterone, which is not widely available. If oral contraceptives are desirable for the patient, progestin-dominant pills may be tried instead of a diuretic or natural progesterone. For those patients whose symptoms are resistant to all of the aforementioned therapy, bromocriptine (Parlodel) or danazol (Danocrine) can be added to the regimen; these drugs, however, should be prescribed only by practitioners experienced in their use.